Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC (LSE: HIK) is a multinational pharmaceutical company headquartered in London, UK, and incorporated in England and Wales in 2005. The business was founded in 1978 in Amman, Jordan, and it remains a major employer there. It is publicly listed on the London Stock Exchange. Company and third-party sources put headcount at roughly 9,400–9,600 employees, with FY2025 revenue of about $3.3 billion (roughly £2.5 billion) and a market capitalization in the £3 billion range.

Operations. Hikma develops, manufactures and markets generic, branded and in-licensed medicines across three reporting segments: Injectables (generic injectable medicines supplied to hospitals in North America, Europe and MENA); Branded (branded generics and in-licensed patented products sold across the Middle East and North Africa, with a focus on oncology and chronic diseases); and Hikma Rx (US oral, respiratory and specialty generics, including prescription nasal sprays). The company reports 29 manufacturing plants, three R&D hubs and more than 800 products, and describes itself as a top-three US supplier of generic injectables.

Litigation posture. This is an operating company, not a patent assertion entity: in the tracked data it appears as a defendant in one case and as a plaintiff in none, consistent with a generic manufacturer defending brand-owner infringement suits. The single tracked matter was filed in the District of New Jersey — near the company's US generics operations in Eatontown, New Jersey — rather than a plaintiff-friendly venue such as the Eastern District of Texas.

Notable case. Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. et al. (D.N.J., filed 2012-10-26) is part of Jazz's patent litigation over Xyrem/sodium oxybate against generic ANDA filers. Hikma is connected to Roxane through its 2015–2016 acquisition of Boehringer Ingelheim's US generics business, Roxane Laboratories, for roughly $2 billion in cash and stock; the business was renamed West-Ward Columbus and later Hikma Labs/US operations. The FTC reviewed and conditioned that acquisition. Hikma's tracked patent-litigation footprint is therefore minimal and stems from its US generics subsidiary rather than from any assertion activity.